Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study

Clinical Therapeutics

Volumn 31, Issue 12, 2009, Pages 2824-2838

  Davidson, Michael H ^a,b   Rooney, Michael W ^b   Drucker, Joan ^b   Eugene Griffin, H ^c   Oosman, Sonia ^c   Beckert, Michael ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b RADIANT RESEARCH   (United States)

^c LifeCycle Pharma Inc   (United States)

^d LifeCycle Pharma   (Denmark)

Author keywords

atorvastatin; dyslipidemia; fenofibrate; fixed dose combination (FDC) tablet; monotherapy

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORFEN; ATORVASTATIN; ATORVASTATIN PLUS FENOFIBRATE; C REACTIVE PROTEIN; CREATININE; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PHOSPHOLIPASE A2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ERYTHEMA; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; INSOMNIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROCETOFEN; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; TABLETS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 74549173160     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.12.007     Document Type: Article

References (25)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
2. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
3. Davidson M.H. Reducing residual risk for patients on statin therapy: The potential role of combination therapy. Am J Cardiol 96 (2005) 3K-13K discussion
4. Davidson M.H. Reducing residual risk for patients on statin therapy: The potential role of combination therapy. Am J Cardiol 96 (2005) 34K-35K
5. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial [published correction appears in Lancet. 2006; 368:1415, 1420]. Lancet 366 (2005) 1849-1861
6. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol. 99 (2007) 3C-18C
7. Davidson M.H. Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 5 (2006) 145-156
8. Keating G.M., and Croom K.F. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67 (2007) 121-153
9. Centers for Disease Control and Prevention, Department of Health and Human Services. Lipid Standardization Program. http://www.cdc.gov/labstandards/lsp.htm Accessed November 18, 2009
10. Kutner M.H., Nachtsheim C.J., Neter J., and Li W. Applied Linear Statistical Models. 5th ed. (2005), McGraw-Hill Irwin, Boston, Mass
11. Davidson M.H., Bays H.E., Stein E., et al., TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 29 (2006) 268-273
12. Fenoglide (fenofibrate) [prescribing information] (2009), Sciele Pharma, Inc, Atlanta, Ga. http://www.fenoglide.com/html/dosing.html Accessed November 10, 2009
13. Antara (fenofibrate capsules) [prescribing information] (2007), Oscient Pharmaceuticals Corporation, Waltham, Mass. http://www.antararx.com/ Accessed November 10, 2009
14. Trilipix (fenofibric acid delayed release capsules) [prescribing information] (2008), Abbott Laboratories, North Chicago, Ill. http://rxabbott.com/pdf/trilipix_pi.pdf Accessed November 10, 2009
15. Lofibra (fenofibrate tablets) [prescribing information] (2003), Gate Pharmaceuticals, Sellersville, Pa. http://www.lofibra.com/PrescribingInfo.pdf Accessed November 10, 2009
16. Goldberg A.C., Bays H.E., Ballantyne C.M., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 103 (2009) 515-522
17. Athyros V.G., Papageorgiou A.A., Athyrou V.V., et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 25 (2002) 1198-1202
18. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 45 (2005) 1649-1653
19. Ginsberg H.N. Hypertriglyceridemia: New insights and new approaches to pharmacologic therapy. Am J Cardiol 87 (2001) 1174-1180
20. Ginsberg H.N. Hypertriglyceridemia: New insights and new approaches to pharmacologic therapy. Am J Cardiol 87 (2001) A4
21. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31 (2003) 1066-1069
22. Jones P.H., Davidson M.H., Kashyap M.L., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis. 204 (2009) 208-215
23. Mohiuddin S.M., Pepine C.J., Kelly M.T., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study. Am Heart J 157 (2009) 195-203
24. Grundy S.M., Vega G.L., Yuan Z., et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) [published correction appears in Am J Cardiol. 2006;98:427-428]. Am J Cardiol 95 (2005) 462-468
25. Farnier M., Dejager S., and French Fluvastatin Study Group. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol. 85 (2000) 53-57